An article by Prof. Farhad Hafezi, MD, PhD, FARVO, Medical Director of the ELZA Institute, published in the November/December issue of Cataract and Refractive Surgery
The 18th CXL Experts’ Meeting, led by ELZA’s CMO, Prof. Farhad Hafezi, was held last weekend in Zurich, Switzerland.
Corneal cross-linking has been shown to be a effective treatment for arresting the progression of keratoconus, and this study adds to the growing body of evidence supporting its use in patients of all ages.
This month’s issue of Ophthalmology Times Europe saw the publication of a review article, “The pathophysiology and pathomorphology of corneal ectasia” authored by Prof. Hafezi, Medical Director of the ELZA Institute, and Dr. Omid Kermani, Managing Director at Augenklinik am Neumarkt in Cologne.
The advantages of performing corneal cross-linking (CXL) at the slit lamp are well established. It brings CXL out of the operating theater, to anywhere where
This week saw the publication of ELZA’s better pain management protocol in the Journal of Clinical Medicine, and represents a significant advance in the way pain
Newsflash: CXL reimbursed in Switzerland
Exactly 20 years after the clinical introduction of cross-linking and after more than 2,000 scientific publications on the subject, corneal cross-linking (CXL) for the treatment of progressive keratoconus has now been included in the Swiss healthcare reimbursement system (the “krankenkasse”).
In science, there is a mantra: “publish or perish”. However, there are almost 30,000 academic journals, and quantity does not equal quality. One of the
People with Down Syndrome have a disproportionately higher risk of developing keratoconus than the general population, and many go on to receive corneal cross-linking (CXL)
Can combining corneal OCT and air puff tonometry help better diagnose the earliest stages of keratoconus? That was the question ELZA researcher, Dr. Nanji Lu,
